A phase II, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma
Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Robert M. Wenham(Moffitt Cancer Center), Emese Zsíros, Robert P. Edwards(Cancer Research UK Technology), Igor Gorbatchevsky(Theravance Biopharma (United States)), Robert J. Brown(Aduro BioTech (United States)), Samuel Suzuki(Theravance Biopharma (United States))
Cited by 6
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508
Management of women who test positive for high-risk types of human papillomavirus: the HART study
|The Lancet|2003|505
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332